Open access
Aug 2026
FCGR3A Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab
Background and Objectives Fc gamma receptor 3A (FCGR3A) V158F polymorphism has been shown to modify the response to anti-CD20 therapy across several autoimmune diseases. Ocrelizumab (OCR), an anti-CD20 agent, suppresses inflammatory activity in multiple sclerosis (MS), yet whether FCGR3A V158F polymorphism affects its...
G. Abbadessa, U. Chianese, Claudia Russo et al.
· Neurology(R) neuroimmunology... · 0 citations